American Heart Association
When the Left Heart Goes Bad: Pulmonary Hypertension Due to Left Heart Disease
Cardiovascular Seminar
265-268
Nov 10th , 01:30 PM - 02:45 PM
Sarma Satyam, Reddy Yogesh, Redfield Margaret
Final Pr. ID: -
Authors: Sarma Satyam, Reddy Yogesh, Redfield Margaret
Rosenkranz Stephan, Maron Brad, Simon Marc
Final Pr. ID: -
Authors: Rosenkranz Stephan, Maron Brad, Simon Marc
02 : 00 PM
Debate - Most Patients With CpcPH and RV Dysfunction Should Receive PAH-Targeted Therapies
Thenappan Thenappan, Ghio Stefano, Forfia Paul
Final Pr. ID: -
Authors: Thenappan Thenappan, Ghio Stefano, Forfia Paul
02 : 15 PM
Debate - Most Patients With CpcPH and RV Dysfunction Should NOT Receive PAH-Targeted Therapies
Maron Brad, Gomberg-maitland Mardi, Hemnes Anna, De Marco Teresa
Final Pr. ID: -
Authors: Maron Brad, Gomberg-maitland Mardi, Hemnes Anna, De Marco Teresa
Rosenkranz Stephan, Maron Brad, Simon Marc
Final Pr. ID: -
Authors: Rosenkranz Stephan, Maron Brad, Simon Marc
02 : 15 PM
Debate - Most Patients With CpcPH and RV Dysfunction Should NOT Receive PAH-Targeted Therapies
Maron Brad, Gomberg-maitland Mardi, Hemnes Anna, De Marco Teresa
Final Pr. ID: -
Authors: Maron Brad, Gomberg-maitland Mardi, Hemnes Anna, De Marco Teresa
02 : 00 PM
Debate - Most Patients With CpcPH and RV Dysfunction Should Receive PAH-Targeted Therapies
Thenappan Thenappan, Ghio Stefano, Forfia Paul
Final Pr. ID: -
Authors: Thenappan Thenappan, Ghio Stefano, Forfia Paul
Sarma Satyam, Reddy Yogesh, Redfield Margaret
Final Pr. ID: -
Authors: Sarma Satyam, Reddy Yogesh, Redfield Margaret